Pittsburgh Business Times- UPMC Enterprises, the medical technology investment arm of UPMC, has purchased interest in RxAnte, a company that uses analytics to predict how patients will adhere to the medications they’re prescribed.
RxAnte will continue to operate as an independent company, and the investment from UPMC Enterprises will allow it to expand its offerings for Medicare, Medicaid and commercial populations, and to extend its predictive models and workflow tools to high-cost specialty drugs.
Recent Posts
Meet the Executive: Brent Burns, Executive Vice President
Over the last two decades, Brent Burns has worked in the ever-changing technology and health space. As an executive at UPMC Enterprises, he draws upon his prior experiences every day.
Read More →
A look back at HIMSS 2019
With HIMSS ’19 wrapped up, we reflect on our experiences and learnings from our time in sunny Orlando, Fl.
Read More →
Vivify Health debuts BYOD remote monitoring tech, talks FHIR at HIMSS19
Vivify Health, a UPMC Enterprises portfolio company, debuted their newest product offering last week at …
Read More →